Efficacy and safety of cardiac myosin inhibitors for symptomatic hypertrophic cardiomyopathy: a meta-analysis of randomized controlled trials

IntroductionHypertrophic cardiomyopathy (HCM) is a common genetic heart disorder. It is characterized by left ventricular hypertrophy and impaired cardiac function, with forms categorized into obstructive (oHCM) and nonobstructive (nHCM). Traditional treatments address symptoms but not the underlyin...

Disgrifiad llawn

Manylion Llyfryddiaeth

Prif Awduron:	Anas Abunada, Madiha Shah, Ateesh Kumar, Syeda Lamiya Mir, Dinesh Kumar, Saboor Ahmed, Muhammad Tanzeel, Vikash Kumar, Aashish Meghjiani, Muhammad Basit Ali Siddiqui, Govinda Khatri, Aneesh Rai, Fnu Deepak, Ayush Kumar
Fformat:	Artigo
Iaith:	Inglês
Cyhoeddwyd:	Frontiers Media S.A. 2025-01-01
Cyfres:	Frontiers in Cardiovascular Medicine
Pynciau:	hypertrophic cardiomyopathy cardiac myosin inhibitors mavacamten aficamten LVOT obstruction
Mynediad Ar-lein:	https://www.frontiersin.org/articles/10.3389/fcvm.2024.1477487/full
Tagiau:	Ychwanegu Tag Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!